---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-186853"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2023-07-14T23:59:59+00:00"
generated_at: "2026-06-13T08:14:56.788940+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Frequency Therapeutics to merge with Korro Bio in all-stock deal; combined firm to focus on RNA editing, trade as KRRO

## Summary
- Pre-merger Frequency stockholders expected to own ~8% of combined company; Korro stockholders (incl. new investors) ~92%.
- Korro Bio secures $117M concurrent private financing co-led by Surveyor Capital and Cormorant; pro-forma cash ~$170M at close.
- Lead program: RNA editing therapy for AATD; preclinical data shows correction to 85% normal A1AT protein; IND planned H2 2024.
- Frequency discontinues its MS remyelination program; stockholders may receive CVR for future proceeds from that program.
- Merger expected to close Q4 2023, subject to Frequency stockholder approval; combined company led by Korro management.

## SEC filing metadata
- accession: 0001193125-23-186853
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2023-07-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000119312523186853/0001193125-23-186853-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000119312523186853/d529859d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-186853
- JSON: https://secwatch.observer/filing/0001193125-23-186853.json
- Plain text: https://secwatch.observer/filing/0001193125-23-186853.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.